Clinical evaluation of zavegepant for the acute treatment of migraine

被引：0
作者：
Fan, Huiqiao [1 ]
Wadolowski, Janette [1 ]
Shan, Ryan [1 ]
Contrera, Gianni J. [1 ]
Polomoff, Christina M. [1 ]
机构：
[1] Univ Connecticut, Sch Pharm, Storrs, CT 06269 USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2025年 / 31卷 / 06期
关键词：
BURDEN; PHARMACOKINETICS; PATHOPHYSIOLOGY; PREVALENCE;
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Zavegepant is the first intranasal calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine and offers a new nonoral option for patients. This article reports the findings of a comprehensive literature review to assess zavegepant's safety and effectiveness. Evidence synthesis involved reporting findings from clinical trials and evaluating comparative effectiveness. This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their zavegepant product review in March 2024.
引用
收藏
页码：598 / 602
页数：5
相关论文
共 43 条
[11]   Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine [J].
Buse, Dawn C. ;
Yugrakh, Marianna S. ;
Lee, Lulu K. ;
Bell, Jvawnna ;
Cohen, Joshua M. ;
Lipton, Richard B. .
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (10) :1334-1343
[12]   Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study [J].
Buse, Dawn C. ;
Reed, Michael L. ;
Fanning, Kristina M. ;
Bostic, Ryan ;
Dodick, David W. ;
Schwedt, Todd J. ;
Munjal, Sagar ;
Singh, Preeti ;
Lipton, Richard B. .
JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01)
[13]   Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update [J].
Charles, Andrew C. ;
Digre, Kathleen B. ;
Goadsby, Peter J. ;
Robbins, Matthew S. ;
Hershey, Andrew .
HEADACHE, 2024, 64 (04) :333-341
[14]   Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial [J].
Croop, Robert ;
Madonia, Jennifer ;
Stock, David A. ;
Thiry, Alexandra ;
Forshaw, Micaela ;
Murphy, Abigail ;
Coric, Vladimir ;
Lipton, Richard B. .
HEADACHE, 2022, 62 (09) :1153-1163
[15]   The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine [J].
Edvinsson, Lars .
HEADACHE, 2017, 57 :47-55
[16]   Migraine pathophysiology: lessons from mouse models and human genetics [J].
Ferrari, Michel D. ;
Klever, Roselin R. ;
Terwindt, Gisela M. ;
Ayata, Cenk ;
van den Maagdenberg, Arn M. J. M. .
LANCET NEUROLOGY, 2015, 14 (01) :65-80
[17]   Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment [J].
Fofi, Luisa ;
Altamura, Claudia ;
Fiorentini, Giulia ;
Brunelli, Nicoletta ;
Marcosano, Marilena ;
Barbanti, Piero ;
Vernieri, Fabrizio .
HEADACHE, 2022, 62 (09) :1143-1147
[18]   PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING [J].
Goadsby, Peter J. ;
Holland, Philip R. ;
Martins-Oliveira, Margarida ;
Hoffmann, Jan ;
Schankin, Christoph ;
Akerman, Simon .
PHYSIOLOGICAL REVIEWS, 2017, 97 (02) :553-622
[19]  
Government of Canada, Canada Vigilance adverse reaction online database
[20]   Burden of migraine in the United States -: Disability and economic costs [J].
Hu, XH ;
Markson, LE ;
Lipton, RB ;
Stewart, WF ;
Berger, ML .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (08) :813-818
12345